CRBU Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.90M

-8.75%

-0.323

-17.22%

2.65M

+12.62%

-0.330

-23.26%

2.65M

-0.64%

-0.345

-40.52%

Estimates Revision

The market is revising Downward the revenue expectations for Caribou Biosciences, Inc. (CRBU) for FY2025, with the revenue forecasts being adjusted by -4.55% over the past three months. During the same period, the stock price has changed by -39.64%.

Revenue Estimates for FY2025

Revise Downward

-4.55%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.04%

In Past 3 Month

Stock Price

Go Down

-39.64%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CRBU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRBU is 8.50 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.50

High

10.00

Current: 0.000

Low

7.00

Averages

8.50

High

10.00

BofA

Buy

downgrade

$8 -> $6

2026-01-06

New

Reason

BofA

Price Target

$8 -> $6

2026-01-06

New

downgrade

Buy

Reason

BofA lowered the firm's price target on Caribou Biosciences to $6 from $8 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

H.C. Wainwright

Buy

maintain

$3 -> $9

2025-11-05

Reason

H.C. Wainwright

Price Target

$3 -> $9

2025-11-05

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Caribou Biosciences to $9 from $3 and keeps a Buy rating on the shares. The firm cites the new data for vispa-cel and CB-011 for the target increase.

Citi

Buy

maintain

$5 -> $8

2025-11-03

Reason

Citi

Price Target

$5 -> $8

2025-11-03

maintain

Buy

Reason

Citi raised the firm's price target on Caribou Biosciences to $8 from $5 and keeps a Buy rating on the shares, citing "meaningfully increased conviction" in the allogenic CAR-T value proposition following two "strong" data readouts in patients with relapsed or refractory B cell non-Hodgkin lymphoma and with relapsed or refractory multiple myeloma. The results deliver on previously communicated goals to generate continued allogenic efficacy on par with auto CAR-Ts and bispecifics, the analyst tells investors.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

2025-03-19

Reason

HC Wainwright & Co.

Robert Burns

Price Target

2025-03-19

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Caribou Biosciences Inc (CRBU.O) is -1.18, compared to its 5-year average forward P/E of -4.06. For a more detailed relative valuation and DCF analysis to assess Caribou Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.06

Current PE

-1.18

Overvalued PE

0.01

Undervalued PE

-8.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.85

Current EV/EBITDA

-0.09

Overvalued EV/EBITDA

2.61

Undervalued EV/EBITDA

-6.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

31.17

Current PS

15.02

Overvalued PS

57.35

Undervalued PS

5.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1731.04% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CRBU News & Events

Events Timeline

No data

News

2.0

2025-12-24Globenewswire

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

9.0

2025-12-01Newsfilter

Caribou Biosciences Hosts Panel on vispa-cel to Broaden Patient Access for CAR-T Therapy

2.0

2025-11-04TipRanks

Three Penny Stocks to Keep an Eye on as of November 4, 2025

People Also Watch

Frequently Asked Questions

What is Caribou Biosciences Inc (CRBU) stock price today?

The current price of CRBU is 1.66 USD — it has decreased -1.78 % in the last trading day.

What is Caribou Biosciences Inc (CRBU)'s business?

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.

What is the price predicton of CRBU Stock?

What is Caribou Biosciences Inc (CRBU)'s revenue for the last quarter?

Caribou Biosciences Inc revenue for the last quarter amounts to 2.20M USD, increased 8.60 % YoY.

What is Caribou Biosciences Inc (CRBU)'s earnings per share (EPS) for the last quarter?

Caribou Biosciences Inc. EPS for the last quarter amounts to -0.30 USD, decreased -21.05 % YoY.

What changes have occurred in the market's expectations for Caribou Biosciences Inc (CRBU)'s fundamentals?

How many employees does Caribou Biosciences Inc (CRBU). have?

Caribou Biosciences Inc (CRBU) has 147 emplpoyees as of January 10 2026.

What is Caribou Biosciences Inc (CRBU) market cap?

Today CRBU has the market capitalization of 155.16M USD.